Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

The predictive model demonstrated an 8-year cumulative incidence of TKI failure in the training set of 10% in the low-risk group, 34% in the intermediate risk, and 69% in the high-risk. A model ...

CARDINAL is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics (PK), and efficacy of TERN-701 in patients with relapsed/refractory CML with or ...

Kolibaba, KS, Druker BJ. Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published in Medscape Hematology-Oncology eJournal 3(2), 2000]. Available at ...

The NOTCH1gene encodes a ligand-activated transcription factor and is affected by stabilizing mutations in 10% CLL at diagnosis, 20% chemorefractory CLL and 30% of cases of Richter syndrome.

Myelofibrosis may be diagnosed with a bone marrow biopsy. Chronic myeloid leukemia, chronic eosinophilic leukemia, and chronic neutrophilic leukemia can show abnormal numbers of specific white blood ...

Myeloproliferative diseases are a heterogeneous group of conditions characterized by excessive cellular proliferation of one or more types of peripheral blood cells.

Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both tumour and normal cells to more specific agents and immunotherapy approaches. Targeted agents are directed at ...

Chronic lymphocytic leukemia (CCL) can affect each person differently. Current treatment options range from conservative monitoring to advanced drug therapies and novel agents under review in ...

You may be surprised if your healthcare provider recommends an antidepressant for chronic pain. Is this because she believes you are depressed? Or can antidepressants help with pain even for people ...